<DOC>
	<DOCNO>NCT01565395</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Incobotulinum Toxin A ( Xeomin® ) injection parotid submandibular gland patient Parkinson 's Disease/Parkinsonism Amyotrophic Lateral Sclerosis ( ALS ) troublesome sialorrhea .</brief_summary>
	<brief_title>Incobotulinum Toxin A Sialorrhea Parkinson 's Disease ( PD ) /Parkinsonism Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Participants recruit Parkinson 's disease , Parkinsonism . Inclusion exclusion criterion summarize . Participants screen first visit make sure eligible trial . They undergo baseline test include neurologic evaluation , question assess memory cognitive status evaluation disease status use part Unified Parkinsons 's Disease Ratings Scale ( UPDRS ) routinely use follow disease progression . They give questionnaire evaluate severity drool . Their saliva production measure spit cup 5 minute , twice . At first visit , make sure eligible study perform baseline testing procedure , give either Xeomin placebo ( saline injection without medication ) injections 4 gland produce saliva . They know injection receive . This visit take 2 hour . They follow every month ask side effect , neurologic evaluation ALS-FRS test fill-in questionnaire drool severity . Saliva volume measure do first visit . At either Month 4 5 , participant receive second injection . This `` cross-over '' injection , i.e. , receive Xeomin first injection receive saline second vice versa . Thus , participant receive study medication Xeomin , either first injection second injection 4 month 5 month . The follow second injection one monthly visit 3 month , similar evaluation describe . The follow-up visit take 1 hour .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Hypothesis : Xeomin® injection parotid submandibular gland safe effective treatment troublesome sialorrhea patient PD/Parkinsonism ALS . Inclusion criterion follow : For ALS : 1 . Patients diagnosed ALS elEscorial Criteria , age 2080 troublesome sialorrhea define below** . For PD/ Parkinsonism : 1 . PD , Multiple Systems Atrophy ( MSA ) , Progressive Supranuclear Palsy ( PSP ) diagnose clinical criterion , age 2080 troublesome sialorrhea define below** . **Troublesome sialorrhea define grade 3 ( grade 3 marked excess saliva drool ) UPDRS Part 2 Sialorrhea grade scale : [ 33 ] ( Appendix 1 ) For group : 1 . Swallowing function : FOIS scale* 5 great ( see appendix 1 scale ) 2 . If patient treat medication sialorrhea earlier , medication least 4 week prior baseline evaluation . 3 . If medication sialorrhea time baseline evaluation , dose hold stable throughout period study . 4 . Women child bear age need reliable method birth control duration study . Exclusion criterion For PD ALS : 1 . Current use Coumadin 2 . Concurrent significant medical illness . 3 . History myasthenia gravis LambertEaton Syndrome 4 . Ongoing substance abuse 5 . History unreliable followup 6 . Past use Xeomin® botulinum toxin preparation 7 . Cognitive impairment , define score ≤ 23/30 Mini Mental Status Exam .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ALS</keyword>
	<keyword>PD</keyword>
</DOC>